ARDX vs. KROS, RCKT, DCPH, ARVN, GERN, AMPH, AMRX, MRVI, DYN, and NAMS
Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Keros Therapeutics (KROS), Rocket Pharmaceuticals (RCKT), Deciphera Pharmaceuticals (DCPH), Arvinas (ARVN), Geron (GERN), Amphastar Pharmaceuticals (AMPH), Amneal Pharmaceuticals (AMRX), Maravai LifeSciences (MRVI), Dyne Therapeutics (DYN), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Keros Therapeutics (NASDAQ:KROS) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.
In the previous week, Keros Therapeutics had 2 more articles in the media than Ardelyx. MarketBeat recorded 13 mentions for Keros Therapeutics and 11 mentions for Ardelyx. Keros Therapeutics' average media sentiment score of 0.64 beat Ardelyx's score of 0.49 indicating that Ardelyx is being referred to more favorably in the news media.
Keros Therapeutics currently has a consensus price target of $86.00, suggesting a potential upside of 59.29%. Ardelyx has a consensus price target of $12.81, suggesting a potential upside of 64.47%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Keros Therapeutics.
71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by insiders. Comparatively, 5.5% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Ardelyx received 479 more outperform votes than Keros Therapeutics when rated by MarketBeat users. Likewise, 67.58% of users gave Ardelyx an outperform vote while only 66.67% of users gave Keros Therapeutics an outperform vote.
Ardelyx has higher revenue and earnings than Keros Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.
Keros Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Keros Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -41.36%. Keros Therapeutics' return on equity of -41.65% beat Ardelyx's return on equity.
Summary
Ardelyx beats Keros Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Ardelyx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
